A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ACT 389949 (Primary)
- Indications Metabolic disorders
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Actelion Pharmaceuticals
- 11 Oct 2016 Pooled analysis of 2 trials, including this and another study were published in the British Journal of Clinical Pharmacology.
- 22 Apr 2014 New trial record